Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03258398 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
A Phase 2 study, sponsored by Effector Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT03258398 is a Phase 2 study that has completed, run by Effector Therapeutics. The registered enrollment target is 56 participants.
The verdict
NCT03258398, a Phase 2 study, has completed, sponsored by Effector Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, 2-part, multicenter study in subjects with MSS relapsed/refractory colorectal cancer. The primary objective of Part 1 is to evaluate the safety and tolerability of escalating doses of eFT508 in combination with a fixed dose of avelumab to determine the maximum tolerated dose (MTD) of eFT508 and to select a recommended dose for Part 2. The primary objective of Part 2 is to evaluate antitumor activity of eFT508 at the recommended dose in combination with avelumab or eFT508 monotherapy. Parts 1 and 2 will also evaluate pharmacokinetics (PK) and pharmacodynamics.
Interventions
- DRUG Avelumab
- DRUG eFT508
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-09-18 |
| Est. Completion | 2019-05-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03258398
The ClinicalTrials.gov registry entry for NCT03258398 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Effector Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avelumab is the first listed.
NCT03258398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03258398 about?
NCT03258398 is a clinical study titled "A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer". This is a Phase 2, open-label, 2-part, multicenter study in subjects with MSS relapsed/refractory colorectal cancer. The primary objective of Part 1 is to evaluate the safety and tolerability of escalating doses of eFT508 in combination with a fixed dose of avelumab to determine the maximum tolerate...
What is the current status of trial NCT03258398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2017-09-18. Estimated completion is 2019-05-13.
What interventions are being tested in trial NCT03258398?
The interventions under investigation include: Avelumab (DRUG), eFT508 (DRUG).
Who is sponsoring clinical trial NCT03258398?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.